Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
about
Novel epigenetic target therapy for prostate cancer: a preclinical studyGeriatric considerations in the treatment of advanced prostate cancerUnscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesGleason 6 Prostate Cancer: Translating Biology into Population Health.The challenge of cancer in middle-income countries with an ageing population: Mexico as a case study.Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsImpact of Age, Race and Socio-economic Status on Temporal Trends in Late-Stage Prostate Cancer Diagnosis in Florida.Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review.Temporal changes in the clinical approach to diagnosing prostate cancerImpact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate.Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer.CAG Repeat Number in the Androgen Receptor Gene and Prostate Cancer.Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China.Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men.Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Challenges of managing elderly men with prostate cancer.Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province.Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan.The implications of ageing and life expectancy in prostate cancer treatment.Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Treatment of Metastatic Prostate Cancer in Older Adults.Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms.Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1α activation.(223)Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature.Active Surveillance in Younger Men With Prostate Cancer.Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening.Docetaxel in very elderly men with metastatic castration-resistant prostate cancer.Perspectives on the clinical management of localized prostate cancer.The benefits of risk assessment tools for prostate cancer.Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.It is time to start active treatment in senior adults with prostate cancer.
P2860
Q27330048-C30BC9D4-5FF3-4FBD-8C1A-D08327A572CFQ33598327-58D3183F-C09A-406B-9CE8-60F3B2FCE6DDQ33676037-EB2B29D4-422F-4FBE-8574-67EA60B69A95Q33693397-623B9D16-EE53-409C-98F3-72AC4FD2458DQ33720164-55BEA654-23B5-4898-9606-AC2BFE077E15Q34132305-DE986B32-4931-4E57-8483-D7EE5646E99FQ34470640-79C9449F-7361-47F4-AE93-A496BE6AE3C5Q35619356-2C3092C5-1587-46E2-B4E1-C2FF025BDE54Q36175852-E9E08558-6AA8-4AE6-BA54-A40D8E8A2B5CQ36346584-45933CC5-7906-4786-BBEA-48E993694951Q36382576-0E4B09B2-7877-4C07-B4B0-7DC4BBD53B2DQ36520528-256321A3-DE5C-4B3B-A00F-1645468BB37DQ37027412-38D9918E-A11D-4F29-91D3-3AC459F4FC5FQ37043425-BAA1FC95-06B7-4955-A00D-2134BFFB554DQ37181453-D6D01736-B8A3-494A-9F66-46F620B10F67Q37368324-F864218B-5D81-4364-B5A0-8D5AB77918C0Q37408547-ACEF9B3B-E319-4C57-8E34-8F9A9F7CC5AAQ37455240-76461591-8162-4D23-AD81-D0A226473E80Q37538483-3F3BA462-1D80-4ACD-AEC6-9F2EC527AB68Q38211358-68EA0505-FF7D-4947-9E0B-4C7C78594822Q38267175-C7AD69FE-F9AC-47EF-A83B-F4B73E89BFE7Q38399938-E8F21BB0-57B7-4276-9DE2-D5DE231D77F7Q38505558-A862A3E4-29CF-4F73-8627-70368D84C150Q38736557-F8CD8C20-F4ED-41DA-8153-25AAF4199920Q38784043-C1E47344-1C33-4FE3-82B6-F64402912CEEQ38841385-575A92C2-90D8-4720-A035-1FFAA15E7965Q38944255-B6F67C23-C52D-47AC-863F-BCD2EC32AE45Q39062508-31D0A5CE-3437-49E5-9F2B-5DF2DAE875DEQ39331992-02720032-BE66-49A9-9C06-7F8341B22493Q39428665-607127A8-D717-44A1-AA89-09338B984209Q40073452-0ACD5249-2CA2-4123-9002-316B4ADF8520Q40271880-2E772B6D-4FD1-47F7-9901-1AB9EC17389DQ40820466-4A8813E6-65D2-41B7-9EFD-832769ECAFABQ40902626-A1793E88-8582-41B9-92D7-3D1168FA766EQ40967992-6C5E452B-4A30-4C0D-AC2E-83C7657087D8Q41275386-7E1036DF-E4F3-4675-BAC8-7255C19EDF0CQ41896776-13A63410-4867-4AD7-91B8-C1A978575BE5Q42391610-3B20B1A6-3F59-4936-8D32-35472A860446Q43726825-3CBAFA8E-129E-4541-BC50-B3F196D420AEQ44102241-66C23DF4-7839-421D-83AB-37DEA0AC1EF4
P2860
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Prostate cancer in the elderly ...... nd disease-specific mortality.
@en
Prostate cancer in the elderly ...... nd disease-specific mortality.
@nl
type
label
Prostate cancer in the elderly ...... nd disease-specific mortality.
@en
Prostate cancer in the elderly ...... nd disease-specific mortality.
@nl
prefLabel
Prostate cancer in the elderly ...... nd disease-specific mortality.
@en
Prostate cancer in the elderly ...... nd disease-specific mortality.
@nl
P2093
P2860
P356
P1433
P1476
Prostate cancer in the elderly ...... nd disease-specific mortality.
@en
P2093
Dragan Golijanin
Edward M Messing
Emil Scosyrev
Supriya Mohile
P2860
P304
P356
10.1002/CNCR.26392
P407
P577
2011-10-17T00:00:00Z